The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial-Reference-Cited by-同舟云学术

The Design of the Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Trial

Published:2017-05 Issue: Volume:187 Page:145-155
ISSN:0002-8703
Container-title:American Heart Journal
language:en
Short-container-title:American Heart Journal

Author:

Ho Carolyn Y.^ORCID,McMurray John J.V.,Cirino Allison L.,Colan Steven D.,Day Sharlene M.,Desai Akshay S.,Lipshultz Steven E.,MacRae Calum A.,Shi Ling,Solomon Scott D.,Orav E. John,Braunwald Eugene

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine

Reference31 articles.

1. Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults-Echocardiographic analysis of 4111 subjects in the CARDIA study;Maron;Circulation,1995

2. Clinical course of hypertrophic cardiomyopathy with survival to advanced age;Maron;J Am Coll Cardiol,2003

3. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy

4. ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines;Gersh;Circulation,2011

5. Sudden death in young athletes;Maron;N Engl J Med,2003

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New Perspectives on Early Stage Hypertrophic Cardiomyopathy: Measuring What Matters;Circulation: Heart Failure;2024-08

2. Quality of Life and Exercise Capacity in Early Stage and Subclinical Hypertrophic Cardiomyopathy: A Secondary Analysis of the VANISH Trial;Circulation: Heart Failure;2024-08

3. Unique Aspects of Hypertrophic Cardiomyopathy in Children;Canadian Journal of Cardiology;2024-05

4. Towards etiological treatments in cardiomyopathies;La Presse Médicale;2024-03

5. Angiotensin receptor blockers in patients with hypertrophic cardiomyopathy: A comparison of VANISH and INHERIT randomized trials;American Heart Journal;2023-12